If it is proven that patient responses to anti-PD1/PD-L1 immunotherapy are linearly associated with increased levels of PD-L1 in many types of cancers [31,32,33], then this also demonstrates that the expression of PD-L1 can only partially predict which patients will benefit from therapy. The gene discussed is CD274; the disease is cancer.